BIOMARIN PHARMACEUTICAL INC (BMRN)

Every figure this model derived for BMRN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 118,908,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 874,005,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 3,971,623,000 AssetsCurrent 2026-06-30
current liabilities 1,663,996,000 LiabilitiesCurrent 2026-06-30
equity 6,321,692,000 StockholdersEquity 2026-06-30
interest expense 83,610,000 InterestExpenseNonoperating 2026-06-30
ocf 857,089,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 3,406,614,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 215,330,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up BMRN on one particular measure came for.

RatioValue
cash operating margin15.19
current ratio2.39
current ratio reported2.39
deferred revenue growth-70.37
dilution pct0.35
ebit cagr-2.14
ebit yoy-80.77
fcf margin21.67
growth cv0.55
interest cover1.79
net debt ebitda13.14
operating margin4.38
owner earnings margin15.35
revenue growth11.2
revenue growth per share10.81
roic1.15
rule of 4015.58
sbc pct revenue6.32

What to be careful about

What this model itself distrusts about BMRN's figures. Written by the derivation as it ran, not added afterwards.